CalciMedica Inc (CALC) Stock Analysis
Verdict: AVOID
Heavy insider accumulation and a Phase 2 clinical pipeline are overshadowed by a critical cash runway deficit and negative shareholder equity.
Investment score: 38/100
Analysis as of
Is CalciMedica Inc stock worth reviewing? The TradeMates thesis
CALC is a high-risk micro-cap biotech with promising insider activity but deteriorating balance sheet metrics. The model identifies a high probability of a dilutive equity offering to resolve the -$6.6M equity deficit and fund ongoing Phase 2 trials.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 85/100 (weight 10%)
- Analyst Consensus: 45/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
CalciMedica Inc opportunities and risks
What speaks for CALC
- Strong Insider Accumulation
What speaks against CALC
- Imminent Dilution Risk
Peers and competitors
- LPCN
- AYR.A.CN
- TVRD
- CTXR
- HIND
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CALC | n/a | 0.0x | n/a | 0.0% | 0.0% | -120.8% |
| LPCN | n/a | 6.9x | n/a | -8.2% | -571.1% | -72.8% |
| TVRD | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -142.6% |
| CTXR | n/a | 1.2x | n/a | 37.4% | -823.3% | -467.5% |
| HIND | n/a | 9.3x | n/a | 48.2% | -985.5% | -24.4% |
| Peer median | n/a | 4.1x | n/a | 18.7% | -697.2% | -107.7% |
Frequently asked questions about CalciMedica Inc (CALC)
Is CALC stock a good investment?
The TradeMates model rates CalciMedica Inc as AVOID with an investment score of 38/100. CALC is a high-risk micro-cap biotech with promising insider activity but deteriorating balance sheet metrics. The model identifies a high probability of a dilutive equity offering to resolve the -$6.6M equity deficit and fund ongoing Phase 2 trials. This is algorithmic model output, not personal investment advice.
Is CALC stock a buy?
The TradeMates model verdict for CALC is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.